Research conducted by Greenphire and the Society for Clinical Research Sites (SCRS) highlights sites’ desire for streamlined payment processes
King of Prussia, PA – Greenphire, the global leader in automated clinical payment solutions, and the Society for Clinical Research Sites (SCRS) today released a new survey that revealed the negative impact that manual payment processes have on global clinical research. Results indicated that manual processes take time away from patient care and shift focus away from research.
The survey of 760 sites around the world focused on financial operations, processes and systems, as well as key issues around patient reimbursement. A white paper with the full results of the survey is available here.
“Our survey results show that sites around the world are eager to adopt new technologies which improve financial processes, reduce administrative burden and make more timely payments possible, said Jim Murphy, CEO, Greenphire. “Eliminating manual burdens through technology can vastly improve the patient experience and simultaneously improve the financial health of the investigative site.”
Key findings of the survey, which ran from December 2016 – February 2017, revealed:
“Sites are looking to streamline the way payments are processed and received,” said Christine Pierre, president of SCRS. “These survey findings demonstrate that sites, both in the U.S. and abroad, want to find new ways to cut down on administrative burdens and focus on research. We are excited about the advances being made by solution providers both in the U.S. and around the world.”
About Greenphire
Greenphire is the global leader in automated clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more at www.Greenphire.com.
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in over 45 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Our Voice. Our Community. Your Success. Join the community and collaborate with the Global Experts in Site sustainability. Visit MySCRS.org.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.